Lymphatic Malformation

2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Protara Therapeutics
1 program
1
TARA-002Phase 21 trial
Active Trials
NCT05871970Recruiting38Est. May 2026
Avalo Therapeutics
1 program
1
CERC-006Phase 11 trial
Active Trials
NCT04994002WithdrawnEst. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Protara TherapeuticsTARA-002
Avalo TherapeuticsCERC-006

Clinical Trials (2)

Total enrollment: 38 patients across 2 trials

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Start: Oct 2023Est. completion: May 202638 patients
Phase 2Recruiting

A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations

Start: Sep 2021Est. completion: Jun 2022
Phase 1Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 38 patients
2 companies competing in this space